• Türkçe
    • English
  • Türkçe 
    • Türkçe
    • English
  • Giriş
Öğe Göster 
  •   Açık Erişim Ana Sayfası
  • Avesis
  • Dokümanı Olmayanlar
  • Makale
  • Öğe Göster
  •   Açık Erişim Ana Sayfası
  • Avesis
  • Dokümanı Olmayanlar
  • Makale
  • Öğe Göster
JavaScript is disabled for your browser. Some features of this site may not work without it.

PREVALENCE AND ASSOCIATED FACTORS OF ADVERSE EFFECTS IN CHILDREN AND ADOLESCENTS TREATED WITH SELECTIVE SEROTONIN REUPTAKE INHIBITORS: A CHART REVIEW STUDY SEÇİCİ SEROTONİN GERİ ALIM İNHİBİTÖRLERİYLE TEDAVİ EDİLEN ÇOCUK VE ERGENLERDE YAN ETKİLERİN SIKLIĞI VE İLİŞKİLİ FAKTÖRLER: BİR DOSYA TARAMA ÇALIŞMASI

Tarih
2023
Yazar
Alinay, Hanım Hülya
Coşkun, Murat
Karayağmurlu, Ali
Üst veri
Tüm öğe kaydını göster
Özet
Objective: This study aims to examine the prevalence and associated clinical and sociodemographic factors of adverse effects in medication among naïve young subjects who received selective serotonin reuptake inhibitor (SSRI) monotherapy. Material and Methods: The medical records of 85 patients who had received SSRI monotherapy in a university hospital's child and adolescent psychiatry clinic were reviewed. The subjects who met the inclusion criteria were included in the study. Results: A total of 67 subjects (10.82±3.63 years) were included. More than half (n=39, 58.9%) developed at least one adverse effect possibly associated with SSRI treatment, with psychic (n=25, 37.3%) and autonomic (n=20, 29.9%) adverse effects as well as behavioral activation (n=13, 19.4%) being the most frequently reported. Medication was discontinued in 13 subjects (19.4%) due to adverse effects, with behavioral activation (6 out of 13 subjects) being the most frequent reason for discontinuation. The development of behavioral activation was significantly associated with younger age, diagnosis of obsessive compulsive disorder in the subjects, and psychiatric history in the subjects' fathers (p value<0.05). Conclusions: Despite the fact that SSRIs are generally safe and well-tolerated in young subjects, adverse effects may be frequent, and medication discontinuation may be required under some conditions. Thus, clinicians treating young subjects should be cautious, particularly about the development of behavioral activation. They should also be mindful of the clinical and sociodemographic factors associated with the adverse effects that may arise during SSRI treatment.
Bağlantı
http://hdl.handle.net/20.500.12627/188670
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85149221876&origin=inward
https://doi.org/10.26650/iuitfd.1153370
Koleksiyonlar
  • Makale [92796]

Creative Commons Lisansı

İstanbul Üniversitesi Akademik Arşiv Sistemi (ilgili içerikte aksi belirtilmediği sürece) Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.

DSpace software copyright © 2002-2016  DuraSpace
İletişim | Geri Bildirim
Theme by 
Atmire NV
 

 


Hakkımızda
Açık Erişim PolitikasıVeri Giriş Rehberleriİletişim
sherpa/romeo
Dergi Adı/ISSN || Yayıncı

Exact phrase only All keywords Any

BaşlıkbaşlayaniçerenISSN

Göz at

Tüm DSpaceBölümler & KoleksiyonlarTarihe GöreYazara GöreBaşlığa GöreKonuya GöreTürlere GöreBu KoleksiyonTarihe GöreYazara GöreBaşlığa GöreKonuya GöreTürlere Göre

Hesabım

GirişKayıt

Creative Commons Lisansı

İstanbul Üniversitesi Akademik Arşiv Sistemi (ilgili içerikte aksi belirtilmediği sürece) Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.

DSpace software copyright © 2002-2016  DuraSpace
İletişim | Geri Bildirim
Theme by 
Atmire NV